Jason Luoma, Ph.D.
@jasonluoma.bsky.social
Psychedelics, MDMA, and shame researcher, treatment developer, author, psychologist, and therapy trainer, at the Portland Institute for Psychedelic Science.
I had missed this interesting podcast from 2023 with Matt Johnson at Johns Hopkins, talking about his history of psychedelic research and thoughts on his groundbreaking study on psilocybin-assisted therapy for smoking cessation. #psychedelicscience
November 11, 2025 at 3:20 PM
I had missed this interesting podcast from 2023 with Matt Johnson at Johns Hopkins, talking about his history of psychedelic research and thoughts on his groundbreaking study on psilocybin-assisted therapy for smoking cessation. #psychedelicscience
A comprehensive living systematic review on psychedelics & MDMA for mental disorders just launched - this a really important new resource for tracking the evidence in real-time. #psychedelicscience
EBI-PSYCHE | Home
ebipsyche-database.org
November 10, 2025 at 5:48 PM
A comprehensive living systematic review on psychedelics & MDMA for mental disorders just launched - this a really important new resource for tracking the evidence in real-time. #psychedelicscience
Super important new paper on reports of challenging experiences by therapists who have participated in research trials of psychedelic-assisted therapy. Reveals huge rift between what providers believe is necessary and what industry is developing as a standard. #psychedelicscience
October 30, 2025 at 4:01 PM
Super important new paper on reports of challenging experiences by therapists who have participated in research trials of psychedelic-assisted therapy. Reveals huge rift between what providers believe is necessary and what industry is developing as a standard. #psychedelicscience
Strongest data yet suggesting that repeated MDMA use causes deficits in declarative memory (e.g., memory for new information, words, etc). #psychedelicscience #MDMA
10.1093/brain/awaf391
10.1093/brain/awaf391
October 27, 2025 at 3:33 AM
Strongest data yet suggesting that repeated MDMA use causes deficits in declarative memory (e.g., memory for new information, words, etc). #psychedelicscience #MDMA
10.1093/brain/awaf391
10.1093/brain/awaf391
New review says that after 55+ years of psychedelic research, we have very few empirical studies on music selection for psychedelic-assisted therapy—despite experts calling music central to therapeutic outcomes. #psychedelicscience
October 18, 2025 at 11:07 PM
New review says that after 55+ years of psychedelic research, we have very few empirical studies on music selection for psychedelic-assisted therapy—despite experts calling music central to therapeutic outcomes. #psychedelicscience
Reposted by Jason Luoma, Ph.D.
Thoughtful and well-informed op-ed from @ianlmorgan.bsky.social
Definitely worth a read!
www.the-scientist.com/nih-leadersh...
1/2
Definitely worth a read!
www.the-scientist.com/nih-leadersh...
1/2
NIH Leadership Is Failing Early Career Researchers
Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers.
www.the-scientist.com
October 10, 2025 at 12:01 PM
Thoughtful and well-informed op-ed from @ianlmorgan.bsky.social
Definitely worth a read!
www.the-scientist.com/nih-leadersh...
1/2
Definitely worth a read!
www.the-scientist.com/nih-leadersh...
1/2
Interesting commentary on idea of "nondirective" approach in psychedelics as culturally laden.
Researchers interviewed therapists in clinical trials and "everybody told us they were totally non-directive." #psychedelicscience
Researchers interviewed therapists in clinical trials and "everybody told us they were totally non-directive." #psychedelicscience
September 29, 2025 at 8:04 PM
Interesting commentary on idea of "nondirective" approach in psychedelics as culturally laden.
Researchers interviewed therapists in clinical trials and "everybody told us they were totally non-directive." #psychedelicscience
Researchers interviewed therapists in clinical trials and "everybody told us they were totally non-directive." #psychedelicscience
Will psychedelic researchers finally speak the same language?
A new paper proposes standardized terminology for the field - and some of it is really new - Will it catch on?
Here's what they want to change. #psychedelicscienceRetry
A new paper proposes standardized terminology for the field - and some of it is really new - Will it catch on?
Here's what they want to change. #psychedelicscienceRetry
September 29, 2025 at 12:34 PM
Will psychedelic researchers finally speak the same language?
A new paper proposes standardized terminology for the field - and some of it is really new - Will it catch on?
Here's what they want to change. #psychedelicscienceRetry
A new paper proposes standardized terminology for the field - and some of it is really new - Will it catch on?
Here's what they want to change. #psychedelicscienceRetry
Reposted by Jason Luoma, Ph.D.
New publication 🚨 "AI and the Future of Academic Peer Review" - led by Sebastian Porsdam Mann, with @cam.ac.uk Mateo Aboy, Joel Seah, Zhicheng Lin, Xufei Luo, @biowhal.bsky.social, Hazem Zohny, Timo Minssen, and Julian Savulescu: buff.ly/kP5Y6tN
September 24, 2025 at 8:59 AM
New publication 🚨 "AI and the Future of Academic Peer Review" - led by Sebastian Porsdam Mann, with @cam.ac.uk Mateo Aboy, Joel Seah, Zhicheng Lin, Xufei Luo, @biowhal.bsky.social, Hazem Zohny, Timo Minssen, and Julian Savulescu: buff.ly/kP5Y6tN
An interesting new preprint about self-compassion in psychedelics. Seeing growing research here with Gabrielle Agin-Liebes leading the way. www.researchgate.net/publication/... #psychedelicscience
(PDF) Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion
PDF | Background: Psychedelics can acutely induce mystical experiences and elevated positive mood, which may contribute to the potential benefits of... | Find, read and cite all the research you need ...
www.researchgate.net
August 28, 2025 at 5:10 PM
An interesting new preprint about self-compassion in psychedelics. Seeing growing research here with Gabrielle Agin-Liebes leading the way. www.researchgate.net/publication/... #psychedelicscience
Reposted by Jason Luoma, Ph.D.
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
August 18, 2025 at 1:17 PM
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
Reposted by Jason Luoma, Ph.D.
Love this new review on psychedelics & emotions from colleagues!
One theme—how we measure positive emotions— resonates with our paper on why distinct positive emotions need more focus in psychedelic science, given their potential role in therapeutic benefits: www.tandfonline.com/doi/10.1080/...
One theme—how we measure positive emotions— resonates with our paper on why distinct positive emotions need more focus in psychedelic science, given their potential role in therapeutic benefits: www.tandfonline.com/doi/10.1080/...
August 19, 2025 at 9:10 AM
Love this new review on psychedelics & emotions from colleagues!
One theme—how we measure positive emotions— resonates with our paper on why distinct positive emotions need more focus in psychedelic science, given their potential role in therapeutic benefits: www.tandfonline.com/doi/10.1080/...
One theme—how we measure positive emotions— resonates with our paper on why distinct positive emotions need more focus in psychedelic science, given their potential role in therapeutic benefits: www.tandfonline.com/doi/10.1080/...
New study showing that psilocybin can be given to patients on ventilators, dialysis, and with advanced heart failure.
Zero serious adverse events occurred further demonstrating that psilocybin can be safe with appropriate medical monitoring. #psychedelicscience
Zero serious adverse events occurred further demonstrating that psilocybin can be safe with appropriate medical monitoring. #psychedelicscience
August 17, 2025 at 3:22 PM
New study showing that psilocybin can be given to patients on ventilators, dialysis, and with advanced heart failure.
Zero serious adverse events occurred further demonstrating that psilocybin can be safe with appropriate medical monitoring. #psychedelicscience
Zero serious adverse events occurred further demonstrating that psilocybin can be safe with appropriate medical monitoring. #psychedelicscience
Reposted by Jason Luoma, Ph.D.
Applications close in 10 days - don't miss out on this great opportunity!
ALSO!!! another research role in our lab coming soon – please subscribe for announcement if you’re not eligible for the current one: www.monash.edu/medicine/scs...
ALSO!!! another research role in our lab coming soon – please subscribe for announcement if you’re not eligible for the current one: www.monash.edu/medicine/scs...
August 15, 2025 at 5:35 AM
Applications close in 10 days - don't miss out on this great opportunity!
ALSO!!! another research role in our lab coming soon – please subscribe for announcement if you’re not eligible for the current one: www.monash.edu/medicine/scs...
ALSO!!! another research role in our lab coming soon – please subscribe for announcement if you’re not eligible for the current one: www.monash.edu/medicine/scs...
New analysis reveals a huge disconnect in MDMA therapy pricing: Lykos wants $36,000 for the drug alone, but researchers calculate it it needs to be around $10,500 to be cost saving. This could be the difference between a niche drug for a few vs a breakthrough therapy accessible to millions.
August 9, 2025 at 1:19 PM
New analysis reveals a huge disconnect in MDMA therapy pricing: Lykos wants $36,000 for the drug alone, but researchers calculate it it needs to be around $10,500 to be cost saving. This could be the difference between a niche drug for a few vs a breakthrough therapy accessible to millions.
Odds of winning NIH grants plummet as new funding policy and spending delays bite | Science | AAAS share.google/viASDaYC4l6n...
Odds of winning NIH grants plummet as new funding policy and spending delays bite
Funding multiyear grants up front will sharply cut number of investigators receiving awards
share.google
July 31, 2025 at 6:32 AM
Odds of winning NIH grants plummet as new funding policy and spending delays bite | Science | AAAS share.google/viASDaYC4l6n...
Reposted by Jason Luoma, Ph.D.
Interesting...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
www.cambridge.org/core/journal...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
www.cambridge.org/core/journal...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study | The British Journal of Psychiatry | Cambridge Core
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
www.cambridge.org
July 11, 2025 at 3:07 PM
Interesting...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
www.cambridge.org/core/journal...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
www.cambridge.org/core/journal...
The newest episode of my Research Matters Podcast it out, this time with Louis Castonguay talking about all he's learned forming and managing multiple practice research networks. He was a very entertaining and knowledgeable guest. I learned a ton. jasonluoma.com/podcast/loui... #researchmatterspod
Louis Castonguay, PhD, on Practice Research Networks, Mutual Respect in Science, and the Joy of Collaboration - Jason Luoma, Ph.D.
Episode Description: Louis Castonguay, Ph.D., is a professor of psychology at Penn State University and a leading figure in contemporary psychotherapy research. With a career spanning decades, Dr. Cas...
jasonluoma.com
July 30, 2025 at 9:23 AM
The newest episode of my Research Matters Podcast it out, this time with Louis Castonguay talking about all he's learned forming and managing multiple practice research networks. He was a very entertaining and knowledgeable guest. I learned a ton. jasonluoma.com/podcast/loui... #researchmatterspod
Psychedelics use continues to increase in the USA among people over 25 years old (not for younger cohorts, with a drop in later adolescents. [from 2024 National Survey on Drug Use and Health]
July 30, 2025 at 8:18 AM
Psychedelics use continues to increase in the USA among people over 25 years old (not for younger cohorts, with a drop in later adolescents. [from 2024 National Survey on Drug Use and Health]
Reposted by Jason Luoma, Ph.D.
I’m looking for a postdoc to join me at UCSD, ideally a clinical psychologist PhD who can deliver mindfulness interventions as well as write papers and do analyses. I have one of the world’s largest psychophysiology datasets of opioid misuse, OUD, & chronic pain. Competitive salary. DM or email.
July 27, 2025 at 8:15 PM
I’m looking for a postdoc to join me at UCSD, ideally a clinical psychologist PhD who can deliver mindfulness interventions as well as write papers and do analyses. I have one of the world’s largest psychophysiology datasets of opioid misuse, OUD, & chronic pain. Competitive salary. DM or email.
Reposted by Jason Luoma, Ph.D.
new paper just dropped in Brain and Behaviour, with @bman1285.bsky.social and colleagues: doi.org/10.1002/brb3...
Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience
A thematic analysis of psychedelic experiences was partitioned into three temporal phases: before, during, and after the experience. Themes before the experience were preparatory intentions and perce...
doi.org
July 23, 2025 at 12:24 PM
new paper just dropped in Brain and Behaviour, with @bman1285.bsky.social and colleagues: doi.org/10.1002/brb3...
New report commissioned by Harvard reveals psychedelic training programs are in crisis. After MDMA's FDA rejection, it seems like the rush of new psychedelic trainees that was anticipated has stalled.
July 22, 2025 at 3:30 PM
New report commissioned by Harvard reveals psychedelic training programs are in crisis. After MDMA's FDA rejection, it seems like the rush of new psychedelic trainees that was anticipated has stalled.
Many people report pain relief from psychedelics in surveys, but rigorous animal testing shows ZERO analgesic effects. This new preprint may reveal something crucial about how psychedelics might actually help with pain.
www.biorxiv.org/content/10.1... #psychedelicscience
www.biorxiv.org/content/10.1... #psychedelicscience
Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models
The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical data suggest these putative benefits derive from direct analgesi...
www.biorxiv.org
July 22, 2025 at 3:03 PM
Many people report pain relief from psychedelics in surveys, but rigorous animal testing shows ZERO analgesic effects. This new preprint may reveal something crucial about how psychedelics might actually help with pain.
www.biorxiv.org/content/10.1... #psychedelicscience
www.biorxiv.org/content/10.1... #psychedelicscience
Good example of how route of administration makes a huge difference in dosing. In this study of sublingual dosing, 12mg of 5-MeO-DMT had relatively small subjective effects, but when that much is inhaled or insufflated, it has profound psychedelic effects:
rdcu.be/ew4rJ
rdcu.be/ew4rJ
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
Neuropsychopharmacology - Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind,...
rdcu.be
July 20, 2025 at 6:12 PM
Good example of how route of administration makes a huge difference in dosing. In this study of sublingual dosing, 12mg of 5-MeO-DMT had relatively small subjective effects, but when that much is inhaled or insufflated, it has profound psychedelic effects:
rdcu.be/ew4rJ
rdcu.be/ew4rJ
Interesting article here. suggests that lykos might not need to run another phase three study, and that mdma approval could happen within twelve months. open.substack.com/pub/ecstatic... #psychedelicscience
RFK pushes the accelerator on psychedelic medicines
Good news for Lykos
open.substack.com
July 20, 2025 at 5:13 PM
Interesting article here. suggests that lykos might not need to run another phase three study, and that mdma approval could happen within twelve months. open.substack.com/pub/ecstatic... #psychedelicscience